Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFIC0M)

Drug Name
Cinalukast Drug Info
Synonyms
Cinalukast [USAN:INN]; Ro 24-5913; Cinalukast (USAN/INN); Ro-24-5913; (E)-4-[[3-(2-(4-Cyclobutyl-2-thiazolyl)ethenyl)phenyl]amino]-2,2-diethyl-4-oxobutanoic acid; 3'-((E)-2-(4-Cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid; 4-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}amino)-2,2-diethyl-4-oxobutanoic acid; 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Approved [1]
Therapeutic Class
Antiarrhythmic Agents
Cross-matching ID
PubChem CID
6436135
ChEBI ID
CHEBI:126598
CAS Number
CAS 128312-51-6
TTD Drug ID
DMFIC0M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Leukotriene CysLT1 receptor (CYSLTR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Montelukast DMD157S Allergic asthma CA23.0 Approved [2]
Zafirlukast DMHNQOG Asthma CA23 Approved [3]
Pranlukast DMYHDCA Allergic rhinitis CA08.0 Approved [4]
KP-496 DMCO8UZ Asthma CA23 Phase 2 [5]
BAY-X-7195 DM2XE80 Asthma CA23 Phase 2 [6]
Masilukast DMDTI0L Asthma CA23 Phase 2 [7]
LM-1507.NA DMW6VA0 Asthma CA23 Phase 2 [8]
Iralukast DMQ3RWN Asthma CA23 Phase 2 [9]
YM-57158 DMS31YW Allergic rhinitis CA08.0 Phase 1 [10]
CR-3465 DMT7L30 Allergy 4A80-4A85 Phase 1 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene CysLT1 receptor (CYSLTR1) TTGKOY9 CLTR1_HUMAN Antagonist [1]

References

1 Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5.
2 Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
3 Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45.
4 Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203.
5 Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
6 The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46.
9 Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8.
10 In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.